Pyruvate kinase deficiency

Phase 3 Study (ACTIVATE) to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

Pyruvate kinase deficiency

Phase 3 Study (ACTIVATE-T) Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

Pyruvate kinase deficiency

Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007

Pyruvate kinase deficiency

Phase 2 DRIVE PK Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency

Pyruvate kinase deficiency

Pyruvate Kinase Deficiency Global Longitudinal Registry (PEAK Registry)

Thalassemia (NTD)

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non-Transfusion Dependent Alpha- or Beta-Thalassemia (ENERGIZE)

Thalassemia (TD)

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)

Thalassemia

A Phase 2, Open-label, Multicenter Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Subjects With Non-transfusion-dependent Thalassemia

Sickle cell disease

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease